When combined with LPS-RGD-Nb36-DOX, CD8+ T cells stimulated through the DC/tumor fusion vaccine could specifically destroy matched tumor cells, this seems to indicate a safe application, and its greater value is that this treatment strategy may reduce the dose of chemotherapeutic drugs and reduce the risk of adverse effects in antitumor therapy. The gene discussed is CD8A; the disease is neoplasm.